Ask AI

EngageTD: Workshop-Based Training in Tardive Dyskinesia Evaluation and Personalized Care

Expanding use of dopamine receptor–blocking antipsychotic agents for the treatment of many psychiatric conditions beyond schizophrenia, including major depression and bipolar disorder, has increased the number of patients at risk of developing tardive dyskinesia. This educational program provides practical guidance on how to screen for and effectively treat this chronically underrecognized condition in your patients.

Share

Program Content

Events

Activities

TD Workshop Introduction
From Overlooked to Identified: Bringing Tardive Dyskinesia Into Focus
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 21, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Teva.

Teva